OOVA is a technology company.
OOVA has raised $11.0M across 2 funding rounds.
OOVA has raised $11.0M in total across 2 funding rounds.
OOVA is a biomarker health technology company specializing in at-home urine testing for hormone monitoring, initially focused on fertility and expanding into perimenopause, women's health, men's health, infant health, and chronic disease.[1][2][3][5] It builds an AI-powered platform that measures key hormones like luteinizing hormone (LH), progesterone metabolite (PdG), and estrogen metabolite (E3G) with 99% lab-grade accuracy via daily urine strips scanned by a mobile app, serving women seeking fertility insights, perimenopause validation, and clinicians needing real-time data.[4][5] OOVA solves the problem of inaccessible, personalized reproductive health data—especially for the 86% of women without a standard 28-day cycle—by providing quantitative hormone profiles that detect ovulation, fertility windows, PCOS risks, and perimenopause symptoms without blood draws, enabling at-home tracking and HIPAA-compliant provider reports.[1][3][4][5] Growth momentum includes partnerships like Thorne Research, backing from investors such as BBG Ventures and The Helm, trust from 100+ clinics and 400+ providers, a 4.9-star rating, and clinical validation by ASRM, ACOG, and The Menopause Society, with a reported +46% increase in successful pregnancies for fertility patients.[2][5]
OOVA spun out from Mount Sinai Hospital in New York City in 2019 as a fertility diagnostic company, founded by Co-Founder and CEO Aparna (Amy) Divaraniya, PhD (a biomedical engineer), Co-Founder and CTO Jerome Scelza, and a doctor—all of whom faced personal fertility challenges.[1][4] The idea emerged from innovative biochemistry and AI developed at Mount Sinai's Institute for Next Generation Healthcare, involving OB/GYNs, reproductive endocrinologists, and fertility specialists from the start to ensure clinically actionable insights.[1][4] Early traction came from three years of R&D using real human urine samples (no synthetics), a partnership with Thorne Research for direct-to-consumer fertility mapping, and clinician involvement that achieved 75% clinic conversion rates by proving data legitimacy over branding.[1][2][4]
OOVA rides the wave of personalized women's health tech and at-home diagnostics, addressing decades of research neglect where most fertility tools assume a "normal" 28-day cycle, leaving 86% of women underserved.[3] Timing aligns with rising demand for remote monitoring post-COVID, AI-driven precision medicine, and perimenopause awareness amid aging populations. Market forces like clinician data gaps, HIPAA-compliant telehealth integration, and expansion into men's/infant/chronic disease via 55+ biomarkers position it to disrupt $50B+ fertility and hormone testing markets.[2][5] It influences the ecosystem by setting standards for quantitative at-home hormone data, bridging consumers and providers, and enabling outcomes like higher pregnancy rates while scaling to broader biomarker health.[1][2][5]
OOVA is poised to evolve from a fertility leader into a multi-biomarker diagnostics platform, with near-term launches in perimenopause (already live), men's health, infant health, and chronic disease within 1-5 years.[2][5] Trends like AI personalization, telehealth growth, and women's health investment (e.g., clinician-validated data) will accelerate adoption, potentially capturing shares in expanding at-home testing amid regulatory nods from medical societies.[5] Its influence may grow by powering provider workflows and consumer empowerment, solidifying OOVA as the go-to for demystifying bodies through trusted, scalable data—echoing its mission to make women's health no longer a black box.[1]
OOVA has raised $11.0M in total across 2 funding rounds.
OOVA's investors include Big Idea Ventures, Byld Ventures, BBG Ventures, Next Play Ventures.
OOVA has raised $11.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $10.0M Series A | Big Idea Ventures, Byld Ventures | |
| Jun 1, 2021 | $1.0M Seed | BBG Ventures, Next Play Ventures |